Profile data is unavailable for this security.
About the company
Solara Active Pharma Sciences Limited is an India-based company offering diversified, commercial active pharmaceutical ingredients (APIs) and contract manufacturing services in over 70 countries. The Company operates through the API segment. Its commercial and research and development products include Albendazole, Aprepitant (Antiemetic), Artesunate, Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone HCL (Anxiolytic), Cetirizine Dihydrochloride, Chlorpromazine Hydrochloride, Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Colesevelam Hydrochloride, Cycloserine (Antitubercular), Ethacrynic Acid (Cardiovascular Agent), Hydralazine Hydrochloride (Anti-Hypertensive), Ibuprofen Sodium Dihydrate (Anti-inflammatory), Mesna (Antineoplastic Detoxifying Agent), Mirabegron (OAB Treatment), Pentoxifylline, and others. The Company works with pharmaceutical companies from North America, Europe, and Japan.
- Revenue in INR (TTM)13.00bn
- Net income in INR-5.61bn
- Incorporated2017
- Employees2.16k
- LocationSolara Active Pharma Sciences Ltd3rd & 4th Floor, Batra CentreNo.28, Sardar Patel Road, GuindyCHENNAI 600032IndiaIND
- Phone+91 4 443446700
- Fax+91 4 422350278
- Websitehttps://solara.co.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hester Biosciences Ltd | 2.99bn | 193.56m | 20.17bn | 642.00 | 101.92 | -- | 53.28 | 6.75 | 23.26 | 23.26 | 350.03 | -- | -- | -- | -- | 4,656,698.00 | -- | 6.15 | -- | 7.69 | 71.52 | 66.64 | 7.34 | 12.83 | -- | 2.26 | -- | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
| Panacea Biotec Ltd | 5.46bn | -279.53m | 20.25bn | 1.15k | -- | -- | 266.61 | 3.71 | -4.58 | -4.58 | 89.84 | -- | -- | -- | -- | 4,761,763.00 | -- | 10.26 | -- | 16.53 | 60.24 | 50.27 | -5.20 | 24.87 | -- | -17.30 | -- | 0.00 | 21.57 | 4.13 | 96.47 | -- | 74.65 | -- |
| Syncom Formulations (India) Ltd | 2.91bn | 285.50m | 20.94bn | 802.00 | 68.35 | -- | 62.57 | 7.20 | 0.326 | 0.326 | 2.99 | -- | -- | -- | -- | 3,626,019.00 | -- | 7.50 | -- | 10.23 | 39.53 | 34.10 | 9.82 | 9.38 | -- | 7.67 | -- | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
| Amrutanjan Health Care Ltd | 4.27bn | 425.73m | 22.57bn | 635.00 | 53.12 | -- | 46.23 | 5.28 | 14.71 | 14.71 | 147.56 | -- | -- | -- | -- | 6,726,040.00 | -- | 16.22 | -- | 20.12 | 49.61 | 53.09 | 9.97 | 13.23 | -- | 212.51 | -- | 18.95 | 10.96 | 10.71 | 12.90 | 12.46 | 26.93 | 16.43 |
| Themis Medicare Ltd | 4.08bn | 500.16m | 23.77bn | 1.54k | 47.57 | -- | 38.57 | 5.83 | 5.43 | 5.43 | 44.31 | -- | -- | -- | -- | 2,648,322.00 | -- | 11.12 | -- | 16.46 | 63.51 | 60.32 | 12.26 | 14.96 | -- | -- | -- | 7.59 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
| IOL Chemicals and Pharmaceuticals Ltd. | 20.72bn | 1.19bn | 28.29bn | 2.78k | 23.86 | -- | 15.30 | 1.37 | 20.20 | 20.20 | 353.05 | -- | -- | -- | -- | 7,461,253.00 | -- | 14.91 | -- | 19.45 | 33.96 | 34.54 | 5.72 | 12.00 | -- | 10.06 | -- | 10.59 | -3.80 | 4.82 | -3.39 | -10.70 | 35.27 | -- |
| Dishman Carbogen Amcis Ltd | 24.16bn | -2.48bn | 28.62bn | 1.13k | -- | -- | 165.73 | 1.18 | -15.81 | -15.81 | 154.06 | -- | -- | -- | -- | 21,344,260.00 | -- | -0.3986 | -- | -0.4888 | 79.30 | 73.83 | -10.27 | -1.54 | -- | -0.7216 | -- | -- | 8.41 | 4.91 | -414.93 | -- | -0.3175 | -- |
| SMS Pharmaceuticals Ltd | 7.38bn | 569.64m | 30.22bn | 1.20k | 52.89 | -- | 33.96 | 4.09 | 6.75 | 6.75 | 87.48 | -- | -- | -- | -- | 6,168,549.00 | -- | 5.43 | -- | 7.33 | 30.12 | 33.30 | 7.69 | 7.87 | -- | 4.21 | -- | 6.17 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Solara Active Pharma Sciences Ltd | 13.00bn | -5.61bn | 31.68bn | 2.16k | -- | -- | -- | 2.44 | -143.75 | -143.75 | 334.17 | -- | -- | -- | -- | 6,030,149.00 | -- | -2.44 | -- | -3.84 | 37.34 | 41.16 | -43.17 | -4.49 | -- | -1.57 | -- | -- | -10.73 | -1.45 | -2,458.12 | -- | -4.81 | -- |
| Indoco Remedies Ltd | 18.22bn | 766.90m | 34.06bn | 5.93k | 44.80 | -- | 19.56 | 1.87 | 8.25 | 8.25 | 178.33 | -- | -- | -- | -- | 3,072,462.00 | -- | 6.88 | -- | 9.85 | 68.61 | 65.59 | 4.10 | 6.93 | -- | 2.95 | -- | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 34.42bn | 1.23k | -- | 108.86 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| RPG Life Sciences Limited | 6.00bn | 923.20m | 34.94bn | 1.27k | 37.84 | -- | 31.63 | 5.83 | 55.82 | 55.82 | 362.60 | -- | -- | -- | -- | 4,721,969.00 | -- | 16.07 | -- | 21.77 | 68.42 | 62.99 | 15.39 | 11.99 | -- | 220.43 | -- | 29.27 | 13.50 | 12.01 | 29.60 | 51.98 | 28.60 | 46.14 |
| Gufic BioSciences Ltd | 8.14bn | 863.69m | 40.16bn | 1.45k | 46.04 | -- | 38.82 | 4.93 | 8.70 | 8.70 | 81.95 | -- | -- | -- | -- | 5,624,707.00 | -- | 11.46 | -- | 19.21 | 52.39 | 45.79 | 10.60 | 10.46 | -- | 8.09 | -- | 1.31 | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| SeQuent Scientific Ltd | 14.27bn | 54.87m | 43.00bn | 1.20k | 807.64 | -- | 55.35 | 3.01 | 0.2137 | 0.2137 | 57.18 | -- | -- | -- | -- | 11,939,190.00 | -- | 1.09 | -- | 1.76 | 45.38 | 41.97 | 0.9902 | 1.18 | -- | 0.9009 | -- | 35.06 | -3.60 | 5.68 | 70.40 | -- | 6.96 | -- |
Data as of Sep 20 2024. Currency figures normalised to Solara Active Pharma Sciences Ltd's reporting currency: Indian Rupee INR
11.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| First Sentier Investors (Singapore)as of 31 May 2024 | 2.10m | 4.38% |
| The Caisse de d�p�t et placement du Qu�becas of 31 Dec 2023 | 1.23m | 2.57% |
| Think Investments LPas of 30 Sep 2023 | 875.44k | 1.82% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Aug 2024 | 615.00k | 1.28% |
| Route One Investment Co. LPas of 30 Sep 2023 | 521.31k | 1.09% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 172.87k | 0.36% |
| SSgA Funds Management, Inc.as of 05 Sep 2024 | 123.31k | 0.26% |
| Dimensional Fund Advisors Ltd.as of 30 Jun 2024 | 13.05k | 0.03% |
| DFA Australia Ltd.as of 31 Jul 2024 | 632.00 | 0.00% |
| American Century Investment Management, Inc.as of 05 Sep 2024 | 421.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 31 Aug 2024Source: FactSet Research Systems Inc.
